Related Experiment Video
Updated: Mar 9, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Clinical Trials of Antiangiogenesis Therapy on Gastric Cancer
1Toronto General Hospital, University Health Network (UHN), University of Toronto, Toronto, ON M5G 1L7, Canada.
Abstract:
Both malignant tumor growth and metastasis are dependent upon angiogenesis, a process of new blood vessel formation. Inhibition of this process by specific inhibitors might be able to control tumor growth and metastasis. Therefore, antiangiogenesis thereapy is considered a promising strategy and being studied worldwide. A wide variety of angiogenesis inhibitors have been identified and some of them are under clinical trials in the advanced patients with cancer including gastric cancer. This review summarizes the development and progress of angiogenesis inhibitors in recent decades, and discusses the future direction of antiangiogenesis research, and the potential antiangiogenic agents which are most likely to be translated into standard treatment for gastrointestinal cancer patients either alone or combined with other therapies.
Insights
Antiangiogenesis therapy, which inhibits new blood vessel formation, shows promise for controlling malignant tumor growth and metastasis. This review explores current angiogenesis inhibitors and their potential in treating gastrointestinal cancers.
Area of Science:
- Oncology
- Vascular Biology
Background:
- Malignant tumor growth and metastasis rely on angiogenesis, the formation of new blood vessels.
- Inhibiting angiogenesis is a promising strategy to control cancer progression.
- Antiangiogenesis therapy is under extensive global research and clinical trials for various cancers, including gastric cancer.
Conclusions:
- Antiangiogenesis therapy is a key strategy in cancer treatment, particularly for gastrointestinal cancers.
- Further research is needed to translate promising antiangiogenic agents into standard clinical practice.
- Combination therapies involving antiangiogenic agents may offer improved outcomes for cancer patients.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
06:21Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...